Sanofi-Aventis and Lilly in Cialis marketing pact

Share this article:
Sanofi-Aventis has teamed with Eli Lilly in a collaboration to market erectile-dysfunction drug Cialis (tadalafil) to US urologists. 

According to Lilly spokesperson Lee Lang, the campaign hopes to “educate urologists nationwide by providing direct selling support for 2.5 mg and 5 mg doses, as well as for use on an ‘as needed' basis.” Lang explains the decision, noting Sanofi's “strong market position in urology.”
Sanofi-Aventis spokeswoman Noelle Boyd added, “Our sales force has developed trust among urologists over the years.” Sanofi-Aventis markets Uroxatral (alfuzosin HCI), for benign prostatic hyperplasia (BPH), and Taxotere (docetaxel), a chemotherapy indicated for prostate cancer, to urologists.

The partnership follows FDA approval in January for a once-daily use in 2.5 mg and 5 mg doses.  Cialis is also known as the “36 hour pill” or the “weekend pill,” due to its longer duration of action in patients. 

A spokesperson for Lilly told CNNMoney that the collaboration with Sanofi-Aventis began on March 13.  On the consumer side, Cialis was recently ranked second in the Top 10 Pharmaceutical Branded Websites Driving Prescription Drug Requests, according to a Manhattan Research study. 
Share this article:
You must be a registered member of MMM to post a comment.

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.